AC Immune announces data on ACI-12589 published in Nature Communications

AC Immune announced the publication of a peer-reviewed paper in Nature Communications showing the ability of an alpha-synuclein positron emission tomography tracer to identify patients with multiple system atrophy. The clinical trial of AC Immune’s wholly owned experimental a-syn PET tracer ACI-12589 was led by the team of Oskar Hansson MD, PhD, at Lund University and Skundefinedne University Hospital, in collaboration with associates at InviCRO LLC, with the support of a grant from The Michael J. Fox Foundation for Parkinson’s Research. The Nature Communications paper describes the first-in-human trial of ACI-12589 comparing healthy control subjects to patients with a-synucleinopathies and other neurological diagnoses. It concludes that ACI-12589 showed a specific and reproducible retention pattern in patients with MSA, indicating that the PET tracer could enable earlier, more accurate diagnosis of MSA and potentially, more precise monitoring of disease progression and responses to new a-syn targeted therapeutics in development.